Open Angle Glaucoma Market (2026 - 2033)

Open Angle Glaucoma Market Summary

The global open angle glaucoma market size was valued at USD 1.0 billion in 2025 and is projected to grow from USD 1.1 billion in 2026 to USD 2.1 billion by 2033, at a CAGR of 9.6% from 2026 to 2033. The market in North America dominated with a revenue share of 41.4% in 2025. Open-angle glaucoma (OAG) is a major cause of irreversible vision loss worldwide, with its burden influenced by population aging, increasing life expectancy, and rising prevalence of myopia. The disease burden varies across regions due to differences in demographics, genetic predisposition, healthcare access, and disease detection rates. These epidemiological trends are expected to increase the need for glaucoma screening, diagnosis, monitoring, and treatment, thereby supporting sustained global demand for OAG-related medical and surgical interventions.

The open-angle glaucoma market is being supported by advances in diagnostic, monitoring, and therapeutic technologies, including optical coherence tomography (OCT), AI-enabled glaucoma screening, advanced visual field testing, minimally invasive glaucoma surgery (MIGS), and sustained drug-delivery solutions. Increasing adoption of these technologies enables earlier disease progression and personalized treatment planning while reducing dependence on conventional approaches. This trend is further supported by the growing global burden of glaucoma, population aging, and increasing emphasis on early diagnosis and long-term disease management to prevent irreversible vision loss.

The epidemiological burden of open-angle glaucoma varies considerably across age groups and geographic regions. Differences in prevalence are influenced by factors such as genetic predisposition, ethnicity, myopia, demographic characteristics, and access to eye-care services. The following data highlights the prevalence and estimated patient burden of open-angle glaucoma across major regions, providing context for the underlying patient population and potential demand for diagnosis and treatment.

Key Global Open-Angle Glaucoma Statistics, 2024

Source: Global Glaucoma Prevalence: Burden and Projection to 2060. American Journal of Ophthalmology.

The increasing focus on early detection and continuous monitoring is creating opportunities across the open-angle glaucoma care pathway. Healthcare providers are increasingly adopting advanced diagnostic tools such as OCT, optical nerve imaging, automated perimetry, and digital monitoring solutions to identify structural and functional changes at earlier stages. At the same time, AI-enabled diagnostic technologies are gaining attention as they can support clinicians in screening larger patient populations and improving the consistency of disease assessment. These developments are particularly relevant as glaucoma can progress gradually without noticeable symptoms until significant vision loss occurs.

Treatment patterns are also evolving as patients and physicians seek effective options that can provide long-term intraocular pressure (IOP) control while improving treatment convenience. Conventional medications, laser therapies, and glaucoma surgeries remain important components of the treatment landscape, while minimally invasive glaucoma surgery (MIGS) is gaining adoption in appropriate patient groups because of its less invasive approach and potential to reduce dependence on topical medications. Sustained drug-delivery systems and other long-acting treatment approaches are also being developed to address challenges associated with daily eye-drop use, including poor adherence and inconsistent dosing.

Regional Prevalence of Primary Open-Angle Glaucoma (POAG)

Source: Global Glaucoma Prevalence: Burden and Projection to 2060. American Journal of Ophthalmology.

Overall, the open-angle glaucoma market is supported by a combination of rising disease burden, aging populations, greater awareness of regular eye examinations, and continued technological advancements across diagnosis and treatment. This shift toward more proactive and technology-driven disease management is expected to remain an important factor shaping the market over the coming years.

Market Dynamics

The open-angle glaucoma market is gaining significant traction as the rising prevalence of glaucoma, aging populations, increasing awareness of eye health, and growing emphasis on controlling intraocular pressure and preventing vision loss are driving demand for surgical treatment procedures. The market encompasses bleb-based and Non-Bleb-Based Procedures glaucoma procedures for the management of open-angle glaucoma, with the procedure landscape including perforating (fistulizing) bleb-based procedures, non-perforating bleb-based procedures, and non-bleb-based procedures. Perforating bleb-based procedures include interventions such as trabeculectomy, while non-perforating approaches aim to reduce intraocular pressure without creating a full-thickness filtration pathway. Non-Bleb-Based Procedures include minimally invasive glaucoma surgery (MIGS) and other procedures that reduce intraocular pressure through alternative outflow pathways or mechanisms.

Market Concentration & Characteristics

The open-angle glaucoma market is moderately concentrated, with several established ophthalmic and medical technology companies holding strong positions across key segments such as glaucoma surgical devices, minimally invasive glaucoma surgery (MIGS) devices, glaucoma drainage implants, laser systems, and ophthalmic diagnostic and monitoring technologies. Major players benefit from broad ophthalmology portfolios, established brands, extensive distribution networks, technological expertise, clinical evidence, and long-standing relationships with ophthalmologists, glaucoma specialists, hospitals, ambulatory surgical centers, and specialty eye-care clinics. Companies such as Alcon, Johnson & Johnson Vision, AbbVie, Glaukos, and Santen Pharmaceutical have established positions across different areas of the glaucoma treatment and management landscape, while other specialized ophthalmic device companies compete in specific procedure categories.

The degree of innovation in the open-angle glaucoma market is high, driven by continuous advancements in minimally invasive glaucoma surgery, micro-bypass implants, laser treatment, pharmacological therapies, and IOP-monitoring technologies. Manufacturers are increasingly developing solutions that aim to provide more consistent IOP reduction, reduce dependence on daily eye drops, improve procedural precision, and address patients whose glaucoma remains uncontrolled despite conventional treatment. For instance, Glaukos' iStent infinite uses three trabecular micro-bypass stents delivered through a single injector and is designed as a standalone treatment for adults with primary open-angle glaucoma whose previous medical and surgical treatment has failed.

Strategic partnerships and collaborations are becoming increasingly important in the open-angle glaucoma market, as companies work with hospitals, ophthalmology centers, universities, research institutes, and other healthcare organizations to accelerate the development and adoption of new glaucoma treatments and technologies. Companies are therefore collaborating across drug discovery, clinical trials, minimally invasive glaucoma surgery (MIGS), diagnostic technologies, patient screening, and treatment access. Such partnerships help manufacturers strengthen clinical evidence, improve physician awareness, expand access to treatment, and enter new geographic markets. A recent example is the Santen Pharmaceutical and Singapore Eye Research Institute (SERI) collaboration announced in December 2025. The companies launched SONIC 2.0, a USD 16.3 million (S$21), three-year research collaboration focused on developing disease-modifying therapies for major eye diseases, including glaucoma. The glaucoma program includes the discovery and optimization of novel compounds and aims to accelerate the translation of laboratory research into clinical-stage candidates.

Regulations have a significant impact on the open-angle glaucoma market because the main treatment options, including prescription drugs, minimally invasive glaucoma surgery (MIGS) devices, glaucoma drainage implants, laser systems, and drug-delivery implants, are subject to regulatory requirements before they can be commercialized. In the U.S., the FDA evaluates glaucoma medicines through the drug approval process, while implantable glaucoma devices are regulated as medical devices and may require premarket approval (PMA) supported by clinical and non-clinical evidence.

The threat of procedure substitutes in the open-angle glaucoma market is moderate because several treatment approaches can be used to lower intraocular pressure (IOP), and the choice depends on disease severity, IOP level, progression, patient adherence, and the patient's overall clinical condition. The main alternatives include topical IOP-lowering medications, laser trabeculoplasty, minimally invasive glaucoma surgery (MIGS), glaucoma drainage implants, and conventional filtering surgery such as trabeculectomy. Because these approaches address the same overall treatment goal, reducing IOP and slowing glaucoma progression, an increase in the use of one treatment can limit demand for another. The FDA recognizes medications, laser treatment, MIGS, and other incisional glaucoma surgeries as alternative treatment options for patients with primary open-angle glaucoma.

Regional expansion is an important growth strategy in the open-angle glaucoma market, as companies are strengthening their presence in established markets while targeting regions with growing glaucoma patient populations and expanding access to ophthalmic care. North America and Europe remain important markets due to their mature healthcare systems, large networks of ophthalmologists and glaucoma specialists, established reimbursement systems, and strong adoption of prescription medicines, laser treatments, MIGS, and glaucoma implants. At the same time, companies are increasingly expanding into Asia-Pacific, Latin America, and the Middle East, where aging populations, increasing awareness of glaucoma, improving diagnostic infrastructure, and growing healthcare investment are creating opportunities for earlier diagnosis and long-term disease management.

Analyst Perspective

The global open-angle glaucoma market is positioned at the intersection of several long-term ophthalmic and healthcare trends, including the rising prevalence of glaucoma, an aging global population, increasing incidence of diabetes and myopia, and growing emphasis on early detection and long-term intraocular pressure (IOP) management. Open-angle glaucoma, particularly primary open-angle glaucoma (POAG), is a major cause of irreversible vision loss and often progresses without noticeable symptoms during its early stages, increasing the need for regular screening, diagnosis, and continuous disease management. The growing number of patients requiring long-term IOP control is creating opportunities for pharmaceutical companies, laser technology providers, and ophthalmic device manufacturers offering glaucoma medications, selective laser trabeculoplasty (SLT), minimally invasive glaucoma surgery (MIGS), and glaucoma drainage devices.

Procedure Insights

The bleb-based procedures segment dominated the market and held the largest revenue share of 52.2% in 2025. Bleb-based procedures, including trabeculectomy and glaucoma drainage device procedures, continue to have an important role in the treatment of patients with moderate-to-severe or advanced open-angle glaucoma, particularly when intraocular pressure (IOP) is not adequately controlled with medications, laser therapy, or less invasive procedures. These procedures create an alternative pathway for aqueous humor drainage and can provide substantial IOP reduction, making them an established option for patients requiring stronger pressure control. Demand remains supported by the large number of patients who progress despite medical treatment and require surgical intervention to reduce the risk of further optic nerve damage and irreversible vision loss. However, these procedures generally require more postoperative monitoring and can be associated with complications such as hypotony and bleb-related infections, which has encouraged physicians to carefully select patients who are most likely to benefit from traditional filtration surgery.

The non-bleb-based procedures segment is expected to witness the fastest CAGR of 10.2% over the forecast period. Growth in this segment is driven by increasing physician and patient interest in procedures that reduce IOP while causing less tissue disruption and requiring less intensive postoperative management than conventional filtration surgery. Non-bleb-based approaches include trabecular micro-bypass procedures, canal-based procedures, cyclophotocoagulation, and other MIGS techniques that use the eye's natural drainage pathways or reduce aqueous humor production without intentionally creating a conventional filtering bleb. Recent product and regulatory developments further demonstrate the growing focus on non-bleb-based treatment options. Glaukos reported in January 2026 that more than 3 million iStent devices had been implanted, indicating the continued expansion of trabecular micro-bypass technology in glaucoma treatment.

Type Insights

The standalone segment dominated the market, held the largest revenue share of 84.0% in 2025, and is expected to witness the fastest CAGR over the forecast period. Standalone glaucoma procedures are gaining importance as ophthalmologists increasingly consider intervention before patients progress to advanced disease or require more invasive filtration surgery. Standalone MIGS and other glaucoma procedures allow physicians to directly target IOP without requiring cataract extraction at the same time. The availability of devices specifically cleared for standalone use provides additional treatment options for patients who require IOP reduction but are not undergoing cataract surgery. For example, the iStent infinite is indicated for adults with primary open-angle glaucoma in whom previous medical and surgical treatment has failed, and its design restores aqueous outflow through Schlemm's canal. In June 2025, Glaukos also announced EU MDR certification for iStent infinite, expanding its regulatory availability outside the U.S. and demonstrating continued commercial development of standalone MIGS technologies.

The combined segment is expected to witness the significant CAGR over the forecast period. Combined procedures generally involve performing a glaucoma procedure together with cataract surgery, most commonly cataract extraction with MIGS. Demand for these procedures is rising because glaucoma and cataracts frequently occur in the same older patient population, allowing physicians to address both conditions during a single surgical session. Combining the procedures can reduce the need for a separate glaucoma operation and provide patients with a single postoperative recovery period. The combined approach is also attractive because cataract surgery itself can reduce IOP, while adding a MIGS procedure can provide an additional pressure-lowering effect and potentially reduce the patient's reliance on glaucoma medications. Recent clinical evidence continues to support this treatment approach.

End Use Insights

The outpatient segment held the largest revenue share of 50.9% in 2025 and is expected to witness the fastest growth over the forecast period. The growth is mainly driven by the shift toward minimally invasive and shorter-duration treatments. Procedures such as MIGS, laser-based glaucoma treatments, and selected standalone glaucoma interventions generally involve less tissue disruption, faster recovery, and lower postoperative care requirements than traditional glaucoma surgeries. This trend is also supported by the increasing need to reduce treatment burden for glaucoma patients. Many patients require long-term IOP management, and outpatient procedures can provide an intervention while avoiding the cost, inconvenience, and resource requirements associated with inpatient admission.

The inpatient segment is expected to grow at a significant CAGR over the forecast period. Although many glaucoma procedures are increasingly performed in outpatient settings, inpatient facilities remain important for patients with advanced or difficult-to-control open-angle glaucoma who require more complex surgical intervention. Traditional procedures such as trabeculectomy and glaucoma drainage device implantation may be selected when a very low target IOP is required or when medications, laser therapy, and MIGS are insufficient. These complex cases require greater perioperative monitoring, more intensive postoperative management, and additional hospital resources, supporting continued demand for hospital-based care. The inpatient segment is also supported by the increasing number of elderly glaucoma patients who may have multiple age-related or systemic conditions requiring closer medical supervision around surgery. The inpatient segment is therefore expected to maintain steady demand even as less invasive procedures increasingly shift routine glaucoma care toward outpatient facilities.

Regional Insights

The North America open angle glaucoma market dominated the global industry with a revenue share of 41.4% in 2025. The growth is largely attributed to the region's large aging population, high prevalence of glaucoma, increasing awareness of regular eye examinations, and strong availability of advanced diagnostic and treatment options. Open-angle glaucoma is the most common form of glaucoma in the U.S. and accounts for more than 80% of glaucoma cases, creating a substantial patient population requiring long-term monitoring and intraocular pressure (IOP) management. The U.S. FDA estimates that approximately 3–5 million adults have open-angle glaucoma, while glaucoma remains a leading cause of irreversible blindness in the country. The region also has well-developed ophthalmology infrastructure, including glaucoma specialists, hospitals, ambulatory surgery centers, and specialty eye-care clinics, supporting the use of IOP-lowering medications, laser trabeculoplasty, glaucoma drainage devices, minimally invasive glaucoma surgery (MIGS), and advanced diagnostic technologies.

U.S. Open Angle Glaucoma Market Trends

The open angle glaucoma market in the U.S.is characterized by a large and clinically diverse patient population, strong adoption of pharmaceutical and surgical treatments, and high availability of advanced glaucoma-management technologies. The U.S. market is also seeing increasing attention toward patients whose disease progresses despite conventional treatment or whose IOP remains within the normal range. In 2024, the FDA's Ophthalmic Devices Panel reviewed an ocular pressure-adjusting pump designed as an adjunctive therapy for adults with open-angle glaucoma and an IOP of 21 mmHg or lower, highlighting the ongoing development of alternative approaches to IOP management.

Europe Open Angle Glaucoma Market Trends

The open angle glaucoma market in Europeis growing rapidly, attributed to the region's aging population, high prevalence of glaucoma, substantial levels of undiagnosed disease, and well-established ophthalmic care infrastructure. A 2025 European Eye Epidemiology Consortium study estimated that around 12.3 million people in Europe have glaucoma, of whom approximately 6.9 million remain undiagnosed. Primary open-angle glaucoma (POAG) accounts for approximately 80% of glaucoma cases in Europe, making it the major disease type within the regional glaucoma market. The growing elderly population is expected to further increase the number of patients requiring regular intraocular pressure monitoring, visual-field testing, OCT imaging, medications, laser procedures, and glaucoma surgery.

The UK open angle glaucoma market is steadily expanding, supported by increasing glaucoma burden, high level of undiagnosed disease, and growing need to reduce pressure on NHS ophthalmology services. Primary open-angle glaucoma affects around 2% of people aged over 40 in the UK, and the disease requires long-term monitoring and treatment because vision loss caused by glaucoma cannot generally be reversed. This rising patient burden is driving continued demand for glaucoma screening, OCT, and visual-field diagnostics; IOP-lowering medications; laser treatment; MIGS; and other surgical interventions, while also encouraging the expansion of community-based glaucoma monitoring by optometrists to help manage the increasing pressure on NHS hospital services.

Asia Pacific Open Angle Glaucoma Market Trends

The open angle glaucoma market in the Asia Pacific is experiencing strong growth, driven by the region's rapidly aging population, increasing prevalence of glaucoma, improving access to ophthalmic care, and growing awareness of the importance of early diagnosis and long-term disease management. The region also has a significant need for earlier diagnosis because glaucoma can progress without noticeable symptoms during its initial stages. Increasing investment in hospitals, specialty eye-care centers, diagnostic equipment, and ophthalmic services is therefore supporting the adoption of technologies such as OCT, visual-field analyzers, tonometers, laser trabeculoplasty, minimally invasive glaucoma surgery (MIGS), and glaucoma drainage devices.

The Japan open angle glaucoma market is highly competitive, supported by a rapidly aging population, advanced ophthalmic infrastructure, strong domestic pharmaceutical and medical-device capabilities, and continued investment in glaucoma diagnosis and treatment innovation. Japan has one of the world's oldest populations, with people aged 65 years and above accounting for almost 30% of the population, increasing the need for long-term management of age-related eye diseases such as glaucoma. The country has an established network of ophthalmologists and hospitals and strong domestic participation from companies such as Santen Pharmaceutical, Kowa, NIDEK, and Topcon, supporting the availability of medications, diagnostic technologies, and surgical solutions.

Latin America Open Angle Glaucoma Market Trends

Theopen angle glaucoma market in Latin Americais growing steadily, supported by the region's aging population, increasing prevalence of glaucoma and other chronic diseases, growing awareness of eye health, and gradual improvement in access to ophthalmic diagnosis and treatment. The burden is particularly important because glaucoma can progress without noticeable symptoms in its early stages, making regular eye examinations and long-term monitoring essential. In addition, the increasing prevalence of diabetes across Latin America is supporting demand for regular ophthalmic examinations because diabetes increases the risk of several vision-threatening conditions and adds pressure on already expanding eye-care services. The availability of public-sector glaucoma treatment programs in major markets is also supporting patient access and market development.

The Brazil open angle glaucoma market is growing, driven by significant glaucoma burden, increasing awareness of early diagnosis, and the availability of glaucoma treatment through both public and private healthcare systems. Brazil's Ministry of Health reported in March 2025 that glaucoma affects approximately 3.4% of the population aged over 40, highlighting a substantial patient base requiring long-term monitoring and treatment. The Unified Health System (SUS) provides consultations, diagnostic examinations, follow-up care, medicines, and surgical treatment for eye diseases, including glaucoma, thereby supporting access to treatment for patients who may not be able to afford private care. These developments support continued demand for IOP-lowering medicines, glaucoma diagnostics, laser treatment, and surgical interventions, while the combination of public reimbursement and private ophthalmology services makes Brazil one of the important markets for glaucoma care in Latin America.

Middle East & Africa Open Angle Glaucoma Market Trends

The open angle glaucoma market in the Middle East & Africais experiencing steady growth. Glaucoma is particularly relevant because it can progress without noticeable symptoms in its early stages and therefore requires regular eye examinations, intraocular pressure monitoring, optic-nerve assessment, and long-term treatment. In Saudi Arabia, for example, a 2023 study of glaucoma patients at King Abdulaziz University Hospital found that 66% of diagnosed patients had open-angle glaucoma, with most of these patients aged above 40 years. Across African markets, limited access to specialist eye-care services and a large unmet need for early diagnosis are creating opportunities for glaucoma screening, diagnostic imaging, medicines, laser therapy, and surgical treatment.

The Saudi Arabia open angle glaucoma market has gained ground from thedemand for open angle glaucoma,the country's aging population, increasing burden of chronic diseases, growing awareness of early glaucoma detection, and expansion of healthcare infrastructure under Saudi Vision 2030. A Saudi study conducted at King Abdulaziz University Hospital in Jeddah found that 85.9% of patients with open-angle glaucoma were older than 40 years, highlighting the strong relationship between aging and the country's patient population. The Saudi Ministry of Health recommends regular eye examinations, particularly for people over 40 years, and identifies intraocular-pressure measurement, optic-nerve examination, visual-field testing, and corneal pachymetry as important components of glaucoma diagnosis.

Key Open Angle Glaucoma Company Insights

The global open-angle glaucoma market is highly competitive, with key players such as Alcon, AbbVie, Glaukos Corporation, Santen Pharmaceutical, and others. These companies compete across different areas of the OAG market, including bleb-based glaucoma procedures, Non-Bleb-Based Procedures, minimally invasive glaucoma surgery (MIGS), glaucoma drainage devices, laser-based treatment technologies, and other surgical and disease-management solutions. Leading companies benefit from broad ophthalmic portfolios, strong brands, established distribution networks, technological expertise, clinical evidence, and long-standing relationships with ophthalmologists, glaucoma specialists, hospitals, ambulatory surgical centers, and specialty eye-care clinics. Companies are increasingly focusing on the development and commercialization of MIGS technologies, advanced glaucoma implants, novel surgical platforms, and procedures designed to provide effective intraocular pressure reduction with less invasive intervention.

Key Open Angle Glaucoma Companies

The following key companies have been profiled for this study on the open angle glaucoma market:

• Glaukos Corporation

• Alcon Inc.

• Sight Sciences, Inc.

• Johnson & Johnson Vision Care, Inc.

• New World Medical, Inc.

• IRIDEX Corporation

• Santen Pharmaceutical Co., Ltd.

• Nova Eye Medical Limited

• iSTAR Medical SA

• Carl Zeiss Meditec AG

• Lumenis Ltd.

• ViaLase, Inc.

• Lumibird SA

• Oertli Instrumente AG

Competitive Benchmarking

Recent Developments:

• In July 2025, Alcon announced the U.S. launch of Voyager Direct Selective Laser Trabeculoplasty (DSLT) for the treatment of glaucoma and ocular hypertension. The laser-based system uses image guidance and automated treatment delivery to target the trabecular meshwork without direct contact with the eye, supporting more precise and efficient IOP reduction.

• In June 2025, Glaukos Corporation announced that it received EU Medical Device Regulation (MDR) certification for its iStent infinite and other MIGS therapies, marking its first approvals under the new EU regulatory framework. The certification confirms that iStent infinite and iStent inject W meet stringent EU standards for safety, quality, and effectiveness, supporting the company’s expansion in Europe.

Open Angle Glaucoma Market Report Scope

Global Open Angle Glaucoma Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the open angle glaucoma market report on the basis of procedure, type, end use, and region:

• Procedure Outlook (Revenue, USD billion, 2021 - 2033)

  • Bleb-based Procedures

    • Perforating (Fistulizing) Bleb-based Procedures

    • Non-Perforating Bleb-Based Procedures (NPDS)

  • Non-Bleb-Based Procedures

• Type Outlook (Revenue, USD billion, 2021 - 2033)

  • Standalone

  • Combined

• End Use Outlook (Revenue, USD billion, 2021 - 2033)

  • Inpatient

  • Outpatient

• Regional Outlook (Revenue, USD billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany 

    • France 

    • Italy 

    • Spain 

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • South Korea

    • Thailand

    • Australia

    • India

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The open angle glaucoma market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing—reconciling supply-side and demand-side estimates—and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each open angle glaucoma segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

Customization Table

This report has been delivered with the following In-depth customizations